WilmerHale Counsels Trevi Therapeutics Through IPO and Concurrent Private Placement

WilmerHale Counsels Trevi Therapeutics Through IPO and Concurrent Private Placement

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, has closed its initial public offering of 5,500,000 shares of its common stock at a price of $10.00 per share. The gross proceeds to Trevi from the offering were $55 million. All of the shares in the offering were sold by Trevi and began trading on the Nasdaq Global Market on May 7, 2019. 

In addition, a fund affiliated with New Enterprise Associates agreed to purchase 1,500,000 shares of Trevi’s common stock in a separate private placement concurrent with the completion of Trevi’s IPO at a price per share equal to the IPO price, for gross proceeds of $15 million. 

Stuart Falber led WilmerHale in the representation of Trevi on these transactions, with a team that included Caroline Dotolo, Jeffries Oliver-Li and Sam Rothberg.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel